Crude Extract Shrinks Tumors and Boosts Survival in Mice

Hepatocellular carcinoma (HCC) is the world’s third-deadliest cancer, with limited drug options and high relapse. A 2019 Journal of Microbiology & Biotechnology paper now reports that a crude nattokinase extract from fermented natto cut HCC tumor area by nearly half and improved mouse survival to 32 %. These findings push nattokinase far beyond its cardio fame into a new oncology spotlight.

Can Oral Nattokinase Hit HCC on Multiple Fronts?

Researchers tested whether daily gavage of crude nattokinase extract could
1. Slow primary tumor growth
2. Block angiogenesis (new-blood-vessel formation)
3. Suppress epithelial mesenchymal transition (EMT) markers linked to metastasis. Tumor histology, ultrasound imaging, and biomarker panels (FOXM1, CD31, CD44, vimentin) served as the read-outs.

Key Results: Tumor, Vessel & Marker Drop-Off

Takeaways: Translating Mouse Wins to Human Vision

1. Multi-Target Action
Nattokinase doesn’t just dissolve fibrin; it suppresses FOXM1 and angiogenic markers, hinting at broad anti-cancer utility.
2. Oral Delivery Works
Daily gavage achieved systemic levels high enough to cut tumor growth—a plus for future capsule formats.
3. Future prospects
Dose-escalation and combination trials with sorafenib or immune checkpoint drugs are logical human-trial paths.

FAQ

Q: Is nattokinase a proven cancer drug?
A:No — data are pre-clinical. The mouse study shows promise, but human trials are needed before any oncology claims.

Q: Will nattokinase interfere with chemo?
A: Unknown. Its protease activity could alter drug pharmacokinetics. Always consult an oncologist before combining supplements with chemotherapy.

Q: What dose was used in mice?
A: Mice received the nattokinase crude extract delivering at 7.5 µl/g according to body weight; human-equivalent doses have not been established.